These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23657379)

  • 41. Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies.
    VanDevanter DR; Mayer-Hamblett N
    Curr Opin Pulm Med; 2017 Nov; 23(6):530-535. PubMed ID: 28708817
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Drug updates and approvals: 2018 in review.
    Mospan C; Mospan G; Byland E; Whitaker WB; Xiong L; Dunlap J; Canupp K
    Nurse Pract; 2018 Dec; 43(12):23-32. PubMed ID: 30379711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New drugs 2020, part 3.
    Hussar DA
    Nursing; 2020 Oct; 50(10):32-41. PubMed ID: 32947372
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Exhaled nitric oxide in stable adult cystic fibrosis patients, during exacerbation and following CFTR-modifying treatment.
    Vincken S; Verbanck S; De Wachter E; Vanderhelst E
    Eur Respir J; 2019 May; 53(5):. PubMed ID: 30819814
    [No Abstract]   [Full Text] [Related]  

  • 45. Lumacaftor alone and combined with ivacaftor: preclinical and clinical trial experience of F508del CFTR correction.
    Brewington JJ; McPhail GL; Clancy JP
    Expert Rev Respir Med; 2016; 10(1):5-17. PubMed ID: 26581802
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential.
    Elborn JS; Davies J
    Lancet Respir Med; 2017 Sep; 5(9):681-683. PubMed ID: 28853396
    [No Abstract]   [Full Text] [Related]  

  • 47. Long-term safety and efficacy of lumacaftor-ivacaftor therapy in children aged 6-11 years with cystic fibrosis homozygous for the F508del-CFTR mutation: a phase 3, open-label, extension study.
    Chilvers MA; Davies JC; Milla C; Tian S; Han Z; Cornell AG; Owen CA; Ratjen F
    Lancet Respir Med; 2021 Jul; 9(7):721-732. PubMed ID: 33516285
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cystic fibrosis transmembrane conductance regulator-modifying medications: the future of cystic fibrosis treatment.
    Pettit RS
    Ann Pharmacother; 2012; 46(7-8):1065-75. PubMed ID: 22739718
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del-CFTR.
    Rowe SM; McColley SA; Rietschel E; Li X; Bell SC; Konstan MW; Marigowda G; Waltz D; Boyle MP;
    Ann Am Thorac Soc; 2017 Feb; 14(2):213-219. PubMed ID: 27898234
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Lumacaftor/ivacaftor, a novel agent for the treatment of cystic fibrosis patients who are homozygous for the F580del CFTR mutation.
    Bulloch MN; Hanna C; Giovane R
    Expert Rev Clin Pharmacol; 2017 Oct; 10(10):1055-1072. PubMed ID: 28891346
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Managing the underlying cause of cystic fibrosis: a future role for potentiators and correctors.
    Galietta LJ
    Paediatr Drugs; 2013 Oct; 15(5):393-402. PubMed ID: 23757197
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Survey of patients with cystic fibrosis and caregivers decisions regarding CFTR modulators.
    George A; Smith B; Sawicki GS; Goetz DM
    Pediatr Pulmonol; 2020 Nov; 55(11):2983-2989. PubMed ID: 32589808
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The safety of lumacaftor and ivacaftor for the treatment of cystic fibrosis.
    Talamo Guevara M; McColley SA
    Expert Opin Drug Saf; 2017 Nov; 16(11):1305-1311. PubMed ID: 28846049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Breakthrough therapies: Cystic fibrosis (CF) potentiators and correctors.
    Solomon GM; Marshall SG; Ramsey BW; Rowe SM
    Pediatr Pulmonol; 2015 Oct; 50 Suppl 40(0 40):S3-S13. PubMed ID: 26097168
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lumacaftor-ivacaftor in the treatment of cystic fibrosis: design, development and place in therapy.
    Connett GJ
    Drug Des Devel Ther; 2019; 13():2405-2412. PubMed ID: 31409974
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pathogen acquisition in patients with cystic fibrosis receiving ivacaftor or lumacaftor/ivacaftor.
    Singh SB; McLearn-Montz AJ; Milavetz F; Gates LK; Fox C; Murry LT; Sabus A; Porterfield HS; Fischer AJ
    Pediatr Pulmonol; 2019 Aug; 54(8):1200-1208. PubMed ID: 31012285
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The CF Canada-Sick Kids Program in individual CF therapy: A resource for the advancement of personalized medicine in CF.
    Eckford PDW; McCormack J; Munsie L; He G; Stanojevic S; Pereira SL; Ho K; Avolio J; Bartlett C; Yang JY; Wong AP; Wellhauser L; Huan LJ; Jiang JX; Ouyang H; Du K; Klingel M; Kyriakopoulou L; Gonska T; Moraes TJ; Strug LJ; Rossant J; Ratjen F; Bear CE
    J Cyst Fibros; 2019 Jan; 18(1):35-43. PubMed ID: 29685812
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and efficacy of treatment with lumacaftor in combination with ivacaftor in younger patients with cystic fibrosis.
    Cheng PC; Alexiou S; Rubenstein RC
    Expert Rev Respir Med; 2019 May; 13(5):417-423. PubMed ID: 30929526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. An Observational Study of Outcomes and Tolerances in Patients with Cystic Fibrosis Initiated on Lumacaftor/Ivacaftor.
    Jennings MT; Dezube R; Paranjape S; West NE; Hong G; Braun A; Grant J; Merlo CA; Lechtzin N
    Ann Am Thorac Soc; 2017 Nov; 14(11):1662-1666. PubMed ID: 28406713
    [TBL] [Abstract][Full Text] [Related]  

  • 60. FDA deems in vitro data on mutations sufficient to expand cystic fibrosis drug label.
    Ratner M
    Nat Biotechnol; 2017 Jul; 35(7):606. PubMed ID: 28700545
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.